Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNC-077
- Development stage
- Phase 1
- Lead developer
- Biokin Pharmaceutical
- Modality
- Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
GNC-077 is an innovative multi-specific antibody developed for the treatment of advanced solid tumors, including breast cancer, non-small cell lung cancer, and gastrointestinal cancers. The drug is designed to engage T cells by targeting CD3 and tumor antigens as well as T cell immune checkpoints. This enables the activation, differentiation, and proliferation of T cells while mediating their specific targeting to kill tumor antigen-positive cells. Preclinical studies have demonstrated potent anti-tumor efficacy across various solid tumor models. The drug is currently in phase I clinical trials to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with locally advanced or metastatic solid tumors[1][2][5][7].
- Other names
- GNC 077GNC077GNC-077
02
Targets
CD3 (T-cell surface glycoprotein CD3)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on GNC-077.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNC-077.